Predicting Inchinkoto efficacy, in patients with obstructive jaundice associated with malignant tumors, through pharmacomicrobiomics

Pharmacol Res. 2022 Jan:175:105981. doi: 10.1016/j.phrs.2021.105981. Epub 2021 Nov 17.

Abstract

Inchinkoto (ICKT) is a popular choleretic and hepatoprotective herbal medicine that is widely used in Japan. Geniposide, a major ingredient of ICKT, is metabolized to genipin by gut microbiota, which exerts a choleretic effect. This study investigates the relationship between stool genipin-producing activity and diversity of the clinical effect of ICKT in patients with malignant obstructive jaundice. Fifty-two patients with malignant obstructive jaundice who underwent external biliary drainage were included. ICKT was administered as three packets per day (7.5 g/day) for three days and 2.5 g on the morning of the fourth day. Stool samples were collected before ICKT administration and bile flow was monitored on a daily basis. The microbiome, genipin-producing activity, and organic acids in stools were analyzed. The Shannon-Wiener (SW) index was calculated to evaluate gut microbiome diversity. The stool genipin-producing activity showed a significant positive correlation with the SW index. Stool genipin-producing activity positively correlated with the order Clostridia (obligate anaerobes), but negatively correlated with the order Lactobacillales (facultative anaerobes). Moreover, stool genipin-producing activity was positively correlated to the concentration valeric acid, but negatively correlated to the concentration of lactic acid and succinic acid. The change of bile flow at 2 and 3 days after ICKT administration showed significant positive correlation with genipin-producing activity (correlation coefficient, 0.40 and 0.29, respectively, P < 0.05). An analysis of stool profile, including stool genipin-producing activity, may predict the efficacy of ICKT. Modification of the microbiome may be a target to enhance the therapeutic effect of ICKT.

Keywords: Artemisiae Capillaris flos (PubChem SID: 135286652); Bio-conversion; Gardeniae fructus (PubChem SID: 405231464); Genipin; Genipin (PubChem CID:442424); Geniposide (PubChem CID:107848); Inchinkoto; Inchinkoto (PubChem SID:51091259); Kampo; Microbiome; Obstructive jaundice; Rhei rhizome (PubChem SID: 135325033).

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bile / chemistry
  • Carboxylic Acids / metabolism
  • Cholagogues and Choleretics / therapeutic use*
  • Clostridium / genetics
  • Clostridium / metabolism
  • Drugs, Chinese Herbal / therapeutic use*
  • Feces / chemistry*
  • Female
  • Gastrointestinal Microbiome / drug effects*
  • Gastrointestinal Microbiome / genetics
  • Humans
  • Iridoids / metabolism*
  • Jaundice, Obstructive / drug therapy*
  • Jaundice, Obstructive / microbiology
  • Lactobacillales / genetics
  • Lactobacillales / metabolism
  • Male
  • Middle Aged
  • Neoplasms / drug therapy
  • Neoplasms / microbiology
  • Treatment Outcome

Substances

  • Carboxylic Acids
  • Cholagogues and Choleretics
  • Drugs, Chinese Herbal
  • Iridoids
  • inchinko-to
  • genipin